SCHEMBL4312705

SCHEMBL4312705

CC(C)(C)OC(=O)N1CCC[C@@H]1COc1ccc(I)cc1

nearest known ligand 0.52

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 2/20 0.48
ALOX5AP P20292 3/20 0.47
FEN1 P39748 1/20 0.47
CHEK2 O96017 1/20 0.45
HRH2 P25021 1/20 0.44
HRH1 P35367 1/20 0.44
F2RL3 Q96RI0 2/20 0.43
KDM1A O60341 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4312709 1.00 GPR119 (0.48) GPR119ALOX5APFEN1CHEK2HRH2
SCHEMBL4319188 1.00 GPR119 (0.48) GPR119ALOX5APFEN1CHEK2HRH2
SCHEMBL4314280 0.96 CHEK2 (0.46) GPR119ALOX5APFEN1CHEK2KDM1A
SCHEMBL4314276 0.96 CHEK2 (0.46) GPR119ALOX5APFEN1CHEK2KDM1A
SCHEMBL4307661 0.94 ALOX5AP (0.47) GPR119ALOX5APFEN1CHEK2HRH2
SCHEMBL4318145 0.94 ALOX5AP (0.46) GPR119ALOX5APFEN1CHEK2HRH2
SCHEMBL4307665 0.94 ALOX5AP (0.47) GPR119ALOX5APFEN1CHEK2HRH2
SCHEMBL4310640 0.94 ALOX5AP (0.47) GPR119ALOX5APFEN1CHEK2HRH2
SCHEMBL4318142 0.94 ALOX5AP (0.46) GPR119ALOX5APFEN1CHEK2HRH2
SCHEMBL6535548 0.89 GPR119 (0.49) GPR119ALOX5APFEN1CHEK2HRH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1926708-B1 BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION DECODE GENETICS EHF (IS) 2014-06-18 EP disclosed
US-8598359-B2 Biaryl substituted heterocycle inhibitors of LTA4H for treating inflammation DECODE GENETICS EHF (IS) 2013-12-03 US disclosed
US-20090163462-A1 BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION DECODE GENETICS, EHF (IS) 2009-06-25 US disclosed
US-7402684-B2 Biaryl substituted heterocycle inhibitors of LTA4H for treating inflammation DECODE GENECTICS EHF. (IS) 2008-07-22 US disclosed
EP-1926708-A1 BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION Decode Chemistry, Inc. (US) 2008-06-04 EP disclosed
WO-2007040681-A1 BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION DECODE GENETICS EHF (IS) 2007-04-12 WO disclosed
WO-2007040682-A1 BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION DECODE GENETICS EHF. (IS) 2007-04-12 WO disclosed
US-20070078263-A1 BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION DECODE CHEMISTRY, INC. (US) 2007-04-05 US disclosed
US-20070066820-A1 BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION DECODE CHEMISTRY, INC. (US) 2007-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090163462-A1 BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION LTA4H, LTB4R, LTC4S GPR119 2606/4885ALOX5AP 21/4885FEN1 4133/4885
US-20070066820-A1 BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION LTA4H, LTB4R, LTC4S GPR119 2606/4885ALOX5AP 21/4885FEN1 4133/4885
US-20070078263-A1 BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION LTA4H, LTB4R, LTC4S GPR119 2606/4885ALOX5AP 21/4885FEN1 4133/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.